HECTOR MARCHAND: Open Payments
NPI 1134474091 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,423 in 126 payments from 29 companies in 2025. Trend: 2023 $3,102 · 2024 $3,038 · 2025 $2,423
Food & beverage: $2,423
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $354 |
| Novo Nordisk Inc | 16 | $319 |
| AstraZeneca Pharmaceuticals LP | 8 | $251 |
| Amgen Inc. | 18 | $215 |
| Novartis Pharmaceuticals Corporation | 3 | $155 |
| Abbott Laboratories | 5 | $137 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $128 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Almatica Pharma LLC | 3 | $73 |
| GlaxoSmithKline, LLC. | 4 | $70 |
Products named: Ozempic, AIRSUPRA, LEQVIO, OTEZLA, CARDIOMEMS, JARDIANCE, QULIPTA, Wegovy.
Industry payments across IN — which companies pay providers there.
